5-Amino-1MQ and Muscle: The Regeneration Research
What is 5-amino-1MQ, exactly
5-amino-1-methylquinolinium, usually shortened to 5-amino-1MQ, is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide and does not belong to the GLP-1 or growth-hormone-secretagogue peptide classes sometimes discussed alongside it. It has no FDA-approved indication for any condition, including muscle loss, weight loss, or aging-related frailty. For the underlying enzyme biology, see NNMT inhibition mechanism and NAD metabolism.
Why "muscle regeneration" gets attached to this compound
NNMT sits inside a metabolic pathway connected to NAD+ availability, and NAD+ decline is one of several biological changes associated with aging skeletal muscle. That connection is real at the level of cell and rodent biology, but it is a mechanistic hypothesis, not a demonstrated human outcome. The gap between "this enzyme is in a relevant pathway" and "this compound rebuilds muscle in people" is exactly where most 5-amino-1MQ marketing overreaches.
What does the actual human muscle-aging research field look like right now
Separate from 5-amino-1MQ, sarcopenia and frailty research in older adults is an active and fairly rigorous clinical field. Recent work in this space includes:
- Handgrip strength benchmarked against age- and sex-specific reference values, including in patients with rheumatoid arthritis and after hip fracture, where grip strength and calf circumference predicted mobility recovery.
- Objective gait measures such as stride length variability linked to osteosarcopenia in community-dwelling older women.
- Composite tools like the SARC-F questionnaire and handgrip strength classification systems used to grade functional risk in stroke and hip fracture populations.
- Biomarker work connecting frailty to growth differentiation factor-15 and to the uric acid to prealbumin ratio in geriatric outpatients.
- Non-pharmacologic interventions, including a systematic review of Tai Chi–based programs showing modest gains in muscle function and physical performance in older adults with sarcopenia or frailty.
- Disease-specific muscle loss, such as diabetes affecting muscle strength in cirrhotic patients awaiting liver transplant, and a mouse study showing impaired liver-muscle lactate metabolism causing sarcopenia through lactic acidosis.
This is a real, funded, peer-reviewed field measuring muscle loss in humans with validated tools. None of it evaluated 5-amino-1MQ.
Has any of this research actually tested 5-amino-1MQ
No. Every source cited above studies sarcopenia, frailty, or muscle function through clinical measurement, biomarkers, or non-pharmacologic intervention. None administered 5-amino-1MQ to animals or humans and measured muscle outcomes. If a retailer or content page implies that this body of sarcopenia literature validates 5-amino-1MQ's muscle-building effects, that is a mischaracterization of the citations, not a reflection of what they show. Verification against the original abstract is warranted before repeating any specific claim.
What would actually count as evidence for 5-amino-1MQ and muscle
A credible evidence base would need controlled human trials measuring validated endpoints, things like handgrip strength, calf circumference, gait speed, or lean mass by imaging, before and after 5-amino-1MQ exposure, with appropriate controls and adverse event tracking. Nothing in the current public literature meets that bar. What exists instead is cell-culture and rodent work on NNMT inhibition and NAD-related metabolism, which is a legitimate starting point for hypothesis generation but cannot support a human muscle-regeneration claim on its own.
Evidence-boundary map for 5-amino-1MQ and muscle claims
| Claim | Status | Basis |
|---|---|---|
| 5-amino-1MQ inhibits NNMT | Established mechanism | In vitro/preclinical pharmacology (see mechanism page) |
| NNMT activity relates to NAD+ metabolism | Established biochemistry | Preclinical pathway data |
| NAD+ decline is associated with aging skeletal muscle | Plausible, active research area | Supported by broader aging-muscle literature, not compound-specific |
| 5-amino-1MQ improves muscle mass or strength in animals | Preclinical signal reported by manufacturers, not verified in the sources above | Requires independent verification |
| 5-amino-1MQ improves grip strength, gait speed, or lean mass in humans | Not established | No human trial identified in current sarcopenia literature |
| 5-amino-1MQ is FDA-approved or 503A-listed for any use | Not true | See FDA status page |
Should someone use 5-amino-1MQ for muscle loss or sarcopenia
Sarcopenia and age-related muscle loss have real, guideline-supported management options, including resistance training, adequate protein intake, and treatment of underlying conditions such as cirrhosis or diabetes that independently accelerate muscle loss. A person concerned about declining grip strength, unintended weight loss, or falls should raise this with a clinician who can screen using validated tools like SARC-F, calf circumference, or grip strength testing, and pursue urgent evaluation if there is sudden weakness, unexplained rapid muscle loss, or falls with injury. Substituting an unregulated compound with no human muscle-outcome data for that workup is not a reasonable trade.
Where this fits against other options people compare it to
Readers researching 5-amino-1MQ for body composition often land on comparisons with GLP-1 therapies or with berberine. Those are different questions with different evidence bases; see 5-amino-1MQ vs GLP-1 and 5-amino-1MQ vs berberine for those comparisons, and evidence quality across the 5-amino-1MQ literature for a broader accounting of what has and has not been studied.
What is established, what is plausible, and what is not established
Established: 5-amino-1MQ inhibits NNMT in laboratory settings, and NNMT sits within NAD-related metabolic signaling. Plausible but unproven: that this mechanism translates into meaningful muscle mass or strength changes in living humans. Not established: any clinical trial evidence, in the sarcopenia and frailty literature reviewed here or elsewhere located, that 5-amino-1MQ improves human muscle outcomes, and no regulatory body has approved it for any indication.
Common questions
Is 5-amino-1MQ the same as the peptides used for muscle growth? No. It is a small synthetic molecule that inhibits an enzyme, not a peptide, and it works through a different proposed mechanism than growth-hormone-related peptides.
Does the sarcopenia research cited on this page apply to 5-amino-1MQ? It describes how muscle loss is measured and managed in humans generally. It does not include any study of 5-amino-1MQ itself, and should not be read as evidence for the compound.
Where can I check current regulatory status before considering this compound? See the FDA Peptide Status Tracker and the page-specific 5-amino-1MQ FDA status summary, and confirm the date on any status claim you read.